Targeted therapy for Bladder Cancer

Targeted therapy uses drugs designed to specifically attack cancer cells by targeting molecular changes involved in tumor growth and spread. It’s typically used for advanced or metastatic bladder cancer.

Expand

All Available Treatments

IV (through a vein) =      Pill =

Treatment Type

FGFR Inhibitor

Drug Name
Balversa® (Erdafitinib) (MIBC) (Pill)
Potential Side Effects
Blood sugar changes Mouth/throat changes Eye problems Diarrhea Fatigue/weakness Skin/nail changes
Important Things to Know
  • Bladder Cancer Type: Muscle-Invasive  
  • Used in patients with FGFR genetic alterations (identified through biomarker testing)
  • Typically for advanced or metastatic urothelial carcinoma
  • Regular eye exams may be needed during treatment
     

Treatment Type

Antibody-drug conjugate (ADC)

Drug Name
Padcev® (Enfortumab vedotin) (IV)
Potential Side Effects
Fatigue/weakness Skin/nail changes Neuropathy Blood sugar changes Diarrhea Low blood counts
Important Things to Know
  • Bladder Cancer Type: Muscle-Invasive
  • Used in patients with previously treated metastatic bladder cancer
  • Combines targeted antibodies with cancer-killing agents
  • May be used after chemotherapy and immunotherapy

     

Treatment Type

Antibody-Drug Conjugate (ADC)

Drug Name
Enhertu® (Trastuzumab deruxtecan) (IV)
Potential Side Effects
Nausea/vomiting Fatigue/weakness Low blood counts Lung problems Hair thinning/loss Weight/appetite changes
Important Things to Know
  • Bladder Cancer Type: HER2-positive bladder cancer
  • For bladder cancer with HER2-positive  test results
  • Used when the cancer has spread and other treatments did not work
  • HER2 biomarker testing is needed before treatment
  • May only be available in Clinical trials  
  • Monitor for lung problems